What do systematic reviews say?

Patisiran vs placebo

Patisiran showed no clear difference in number of participants experiencing at least one severe adverse event compared with placebo (low certainty).

• Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
  RR 0.91 [0.64, 1.28]
  1 study · 225 participants
  Low